focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

Share Price Information for Heiq (HEIQ)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 14.00
Bid: 12.75
Ask: 14.10
Change: -0.15 (-1.06%)
Spread: 1.35 (10.588%)
Open: 14.00
High: 14.00
Low: 14.00
Prev. Close: 14.15
HEIQ Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Acquisition of Chem-Tex Laboratories, Inc

2 Dec 2022 07:00

RNS Number : 3428I
HeiQ PLC
02 December 2022
 

2 December 2022

 

HeiQ Plc

("HeiQ" or "the Company")

 

Acquisition of Chem-Tex Laboratories, Inc

 

HeiQ Plc (LSE: HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, is pleased to announce the acquisition of the land and property of Chem-Tex Laboratories, Inc. ("Chem-Tex") in North Carolina, USA ("the Acquisition") for a total consideration of US$2.5 million. US$550,000 will be paid in cash and US$1.95 million in HeiQ Plc shares. The Acquisition will strengthen the Company's footprint in the USA, which is a key market for HeiQ.

 

Since May 2017, HeiQ's US subsidiary, HeiQ ChemTex has leased Chem-Tex's real estate property in Concord, North Carolina to develop and manufacture specialty chemicals for the functional flooring, textile, and industrial chemicals industries. HeiQ has now made a strategic decision to assume ownership of the land and property in order to safeguard past and future investments into its operations site. HeiQ foresees further expansion of the location over the coming years, serving mainly its global textile, functional flooring and industrial chemicals business.  

This Acquisition is expected to improve HeiQ's operating margin in 2023 and beyond and will also enable HeiQ to focus its future manufacturing investments in the USA, which have proven to be less exposed to energy price increases and critical base chemical raw materials availability challenges experienced in Europe in the recent years.

 

The sellers of Chem-Tex are three trusts, the beneficiaries of which are related to a minority shareholding of HeiQ Plc.

Recently joined HeiQ Chemtex Inc. (USA) CEO, Mike Abbott (former Hanes Inc. CTO) said:  

"We are excited to announce the acquisition of Chem-Tex's land and property, which is expected to improve operating margin for 2023 and beyond and also enable further expansion of HeiQ's current footprint in the USA market, that remains resilient in the current volatile macroeconomic environment."

 

Issue of Equity and Total Voting Rights 

 

The Company will issue 2,176,884 new ordinary shares ("Consideration Shares") to the sellers of Chem-Tex, at a price of £0.744 per share, which is the average 5 day closing price prior to signing in order to part satisfy the consideration due. Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission").

 

It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 08.00 a.m. on 8 December 2022.

 

Following Admission, the total number of Ordinary Shares in issue will be 136,734,308 and the total number of voting rights will therefore be 136,734,308. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 

This announcement contains inside information.

 

For further information, please contact:

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibers market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQEAXAFEDLAFFA
12
Date   Source Headline
14th Apr 20227:00 amRNSFY 2021 Trading Update and Notice of Results
24th Feb 20222:55 pmRNSIssue of Equity
17th Feb 20222:35 pmRNSDirector/PDMR Shareholding
14th Feb 20227:00 amRNSHUGO BOSS and LYCRA back new climate positive yarn
3rd Dec 20217:00 amRNSInvestor Presentation
28th Sep 20219:05 amRNSSecond Price Monitoring Extn
28th Sep 20219:00 amRNSPrice Monitoring Extension
28th Sep 20217:00 amRNSInterim Results
20th Sep 20217:00 amRNSNotice of Results and Investor Presentation
16th Jul 20217:00 amRNSCollaboration Agreement with The LYCRA Company
9th Jul 20217:00 amRNSCompletion of Acquisition
28th Jun 20211:45 pmRNSFurther re. Annual General Meeting
25th Jun 20214:40 pmRNSResult of AGM
21st Jun 20214:30 pmRNSAnnual General Meeting Update
15th Jun 20217:00 amRNSAcquisition Life Material Technologies Limited
9th Jun 20217:00 amRNSHeiQ Chrisal water treatment solution contract win
28th May 20217:00 amRNSCreates sustainable textile finishing partnership
20th May 20214:20 pmRNSProgressive initiates coverage
13th May 20217:00 amRNSNotice of AGM
29th Apr 20217:00 amRNSAcquisition of RAS AG
28th Apr 20217:00 amRNSResults for the year ended December 31, 2020
8th Apr 20217:00 amRNSNotice of Results and Investor Presentation
19th Mar 20217:00 amRNSHeiQ Viroblock Agreement with ICP
11th Mar 20217:00 amRNSHeiQ Viroblock Partnership with Berger Paint
3rd Mar 20217:00 amRNSAcquisition of 51% of Industrial Biotech Business
11th Feb 20217:00 amRNSHeiQ Viroblock Contract Win
28th Jan 202111:30 amRNSLaunch of HeiQ Viroblock Permanent
27th Jan 20219:05 amRNSSecond Price Monitoring Extn
27th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20219:05 amRNSSecond Price Monitoring Extn
26th Jan 20219:00 amRNSPrice Monitoring Extension
26th Jan 20217:00 amRNSTrading Update
13th Jan 20217:00 amRNSChange of External Auditor
5th Jan 20212:01 pmRNSPrice Monitoring Extension
4th Jan 20219:05 amRNSSecond Price Monitoring Extn
4th Jan 20219:00 amRNSPrice Monitoring Extension
15th Dec 20207:00 amRNSMajority stake in medical device manufacturer
9th Dec 202011:15 amRNSDirector/PDMR Dealings
9th Dec 20207:00 amRNSInvestor Presentation
7th Dec 20208:00 amRNSAdmission to Trading and First Day of Dealings
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.